Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds
Hims & Hers Health reports Q1 earnings Monday after close, with Wall Street expecting ~$617M revenue. The key focus: how its weight-loss business performs after shifting from compounded GLP-1 drugs to FDA-approved options from Novo Nordisk.
Earnings
